TELA Bio to Participate in Upcoming Needham & Co. 21st Annual Healthcare Virtual Conference
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
TELA Bio, a medical technology company, announced its participation in the Needham & Co. 21st Annual Healthcare Virtual Conference on April 12, 2022, at 2:15 PM ET. TELA Bio focuses on soft-tissue reconstruction solutions that prioritize preserving the patient's anatomy. Management will present at the conference, and interested parties can access the live and archived webcast via their investor relations website. TELA Bio is committed to providing advanced technologies that enhance clinical outcomes while reducing reliance on permanent synthetic materials.
Details
News Market Reaction – TELA
The recorded move for TELA in the trading session of this news was +0.60%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
MALVERN, Pa., March 30, 2022 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s own anatomy, today announced that the Company will participate in the Needham & Co. 21st Annual Healthcare Virtual Conference on April 12th, 2022.
TELA Bio’s management is scheduled to present at the Needham & Co. 21st Annual Healthcare Virtual Conference on April 12th, 2022, at 2:15pm ET. Interested parties can access the live and archived webcast at ir.telabio.com.
About TELA Bio, Inc.
TELA Bio, Inc. (NASDAQ: TELA) is a commercial-stage medical technology company focused on providing innovative technologies that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s own anatomy. The Company is committed to providing surgeons with advanced, economically effective soft-tissue reconstruction solutions that leverage the patient’s natural healing response while minimizing long-term exposure to permanent synthetic materials. For more information, visit www.telabio.com.
Investor Contact
Greg Chodaczek
332-895-3230
ir@telabio.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.